** Shares of consumer healthcare co Kenvue KVUE.N fall ~2% to $20.33 premarket
** Co forecasts 2025 adjusted profit below estimates hit by a stronger dollar and weak demand for its cough and cold products
** Co forecasts flat to 2% growth in 2025 adjusted EPS, compared with $1.14 it earned in 2024
** Analysts expect earnings to grow 5.6% this year, or to $1.21 per share, according to estimates compiled by LSEG
** Reports Q4 sales of $3.66 billion slightly missing estimates of $3.77 billion, hit by low incidences of cold, cough and flu
** Stock fell over 20% since its stock market debut in May 2023
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.